Last reviewed · How we verify
Selective Therapy: Drug — Competitive Intelligence Brief
marketed
Selective therapy
Small molecule
Live · refreshed every 30 min
Target snapshot
Selective Therapy: Drug (Selective Therapy: Drug) — Vanderbilt University Medical Center. Selective therapy targets the drug's molecular mechanism to modulate its activity.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Selective Therapy: Drug TARGET | Selective Therapy: Drug | Vanderbilt University Medical Center | marketed | Selective therapy |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Selective therapy class)
- Vanderbilt University Medical Center · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Selective Therapy: Drug CI watch — RSS
- Selective Therapy: Drug CI watch — Atom
- Selective Therapy: Drug CI watch — JSON
- Selective Therapy: Drug alone — RSS
- Whole Selective therapy class — RSS
Cite this brief
Drug Landscape (2026). Selective Therapy: Drug — Competitive Intelligence Brief. https://druglandscape.com/ci/selective-therapy-drug. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing